SCHEMBL7715

SCHEMBL7715

Cc1cc(I)ccc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.49
TPMT P51580 1/20 0.48
RXRB P28702 2/20 0.47
RXRA P19793 1/20 0.46
PTPRC P08575 1/20 0.46
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPRA P18433 1/20 0.46
PTPRB P23467 1/20 0.46
PTPRE P23469 1/20 0.46
PTPN6 P29350 1/20 0.46
CYP1A2 P05177 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MYC P01106 1/20 0.42
MAP2K2 P36507 1/20 0.41
MAP2K1 Q02750 1/20 0.41
RARB P10826 1/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748562 1.00 IDO1 (0.49) IDO1TPMTRXRBRXRAPTPRC
SCHEMBL4940319 0.83 SMN1; SMN2 (0.40) IDO1TPMTALDH1A1KDM4EHPGD
SCHEMBL1320693 0.83 PTPRC (0.50) IDO1TPMTPTPRCPTPN2PTPN1
SCHEMBL1748053 0.81 MKNK1 (0.46) IDO1TPMTMAP2K2MAP2K1
SCHEMBL522679 0.79 PTPN1 (0.55) TPMTPTPRCPTPN2PTPN1PTPRA
SCHEMBL22226016 0.78 MAP2K1 (0.42) IDO1MAP2K2MAP2K1HPGD
SCHEMBL2351916 0.78 KDM4E (0.49) ALDH1A1MYCKDM4EHPGDHSD17B10
SCHEMBL1498034 0.77 RXRB (0.70) RXRBRXRACYP1A2RARBKDM4E
SCHEMBL44342 0.77 MYC (0.58) TPMTRXRBRXRAPTPN1CYP1A2
SCHEMBL107259 0.77 CSNK2A1 (0.59) RXRBRXRAALDH1A1KDM4ECSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731207-A2 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS Merck Sharp & Dohme LLC (US) 2026-04-29 EP disclosed
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus MERCK SHARP & DOHME LLC 2026-03-03 US disclosed
US-20250235543-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2025-07-24 US disclosed
EP-4522604-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS Merck Sharp & Dohme LLC (US) 2025-03-19 EP disclosed
EP-4522606-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS Merck Sharp & Dohme LLC (US) 2025-03-19 EP disclosed
WO-2025006293-A2 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS MERCK SHARP & DOHME LLC (US) 2025-01-02 WO disclosed
CN-118451078-A Modified proteins and protein degrading agents 上海睿跃生物科技有限公司 2024-08-06 CN disclosed
US-20240241444-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2024-07-18 US disclosed
WO-2024131942-A1 CYCLOPROPANE TLR7 AND TLR8 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海深势唯思科技有限责任公司 2024-06-27 WO disclosed
CN-118239959-A Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof 上海深势唯思科技有限责任公司 2024-06-25 CN disclosed
EP-0674516-A4 1995-10-25 EP disclosed
EP-0674516-A1 ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS AGOURON PHARMACEUTICALS, INC. (US) 1995-10-04 EP disclosed
EP-0672031-A1 CATECHOL DIETHERS AS SELECTIVE PDE IV? INHIBITORS PFIZER INC. (US) 1995-09-20 EP disclosed
US-5374628-A Aryl and heteroaryl(phosphinylmethyl)phosphonate squalene synthetase inhibitors and method E. R. SQUIBB & SONS, INC. (US) 1994-12-20 US disclosed
WO-1994017076-A1 CONDENSED HETEROCYCLIC GLUTAMIC ACID DERIVATIVES AS ANTIPROLIFERATIVE AGENTS AGOURON PHARMACEUTICALS, INC. (US) 1994-08-04 WO disclosed
WO-1994013295-A1 ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS AGOURON PHARMACEUTICALS, INC. (US) 1994-06-23 WO disclosed
WO-1994012461-A1 CATECHOL DIETHERS AS SELECTIVE PDEIV INHIBITORS PFIZER INC. (US) 1994-06-09 WO disclosed
US-5278153-A Hypocholesterolemic or hypolipemic E. R. SQUIBB & SONS, INC. (US) 1994-01-11 US disclosed
EP-0570706-A1 Aryl and heteroaryl (phosphinylmethyl) phosphonate squalene synthetase inhibitors and method E.R. SQUIBB & SONS, INC. (US) 1993-11-24 EP disclosed
US-4935559-A Palladium catalyst EASTMAN KODAK COMPANY (US) 1990-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus NHERF1, ZC3HAV1, SARS1 IDO1 1932/4885TPMT 157/4885RXRB 793/4885
US-20250235543-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, TP53BP1 IDO1 2506/4885TPMT 1860/4885RXRB 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.